Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Vs. India Patent Law Has Repercussions In South Africa

This article was originally published in PharmAsia News

Executive Summary

An India court case involving a Novartis challenge to the nation's patent law is being watched closely around the globe, particularly in South Africa.

You may also be interested in...



Latest Commission Charts Show How Pandemic Is Stalling New Notified Body Appointments

Despite the urgency to have many more notified bodies designated under the MDR and IVDR, COVID-19 fall-out has resulted in a hiatus in their appointment, Commission figures show.

People On The Move: Appointments At RB, GSCF And CMDh

Reckitt hires chief digital officer from Nestlé and shakes up Australia leadership; GSCF names Bayer's Schipper as chair; and Europe's CMDh appoints a new chair.

Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs

During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel